Scopus BioPharma has Huge Scope for Growth. Find Out How!
Scopus BioPharma, Inc. (NASDAQ: SCPS), a biopharmaceutical company, announced the approval of an investigational drug application (IND) for CpG-STAT3siRNA, an immuno-oncology RNA therapy intended for the treatment of multiple cancers. CpG-STAT3siRNA, or CO-sTiRNA™, the company’s lead product candidate is a first-in-class, targeted immuno-oncology gene therapy and...
